| Year |
Citation |
Score |
| 2024 |
Zhu B, Yin H, Zhang D, Zhang M, Chao X, Scimeca L, Wu MR. Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy. Cellular & Molecular Immunology. PMID 38605087 DOI: 10.1038/s41423-024-01153-x |
0.408 |
|
| 2024 |
Wang Y, Buck A, Piel B, Zerefa L, Murugan N, Coherd CD, Miklosi AG, Johal H, Bastos RN, Huang K, Ficial M, Laimon YN, Signoretti S, Zhong Z, Hoang SM, ... ... Wu MR, et al. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects. Molecular Cancer. 23: 56. PMID 38491381 DOI: 10.1186/s12943-024-01952-w |
0.54 |
|
| 2023 |
Suh J, Kim H, Min J, Yeon HJ, Hemberg M, Scimeca L, Wu MR, Kang HG, Kim YJ, Kim JH. Decoupling NAD metabolic dependency in chondrosarcoma by targeting the SIRT1-HIF-2α axis. Cell Reports. Medicine. 101342. PMID 38128534 DOI: 10.1016/j.xcrm.2023.101342 |
0.334 |
|
| 2019 |
Wu MR, Nissim L, Stupp D, Pery E, Binder-Nissim A, Weisinger K, Enghuus C, Palacios SR, Humphrey M, Zhang Z, Maria Novoa E, Kellis M, Weiss R, Rabkin SD, Tabach Y, et al. A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS). Nature Communications. 10: 2880. PMID 31253799 DOI: 10.1038/S41467-019-10912-8 |
0.371 |
|
| 2019 |
Wu MR, Jusiak B, Lu TK. Engineering advanced cancer therapies with synthetic biology. Nature Reviews. Cancer. PMID 30837696 DOI: 10.1038/S41568-019-0121-0 |
0.446 |
|
| 2017 |
Nissim L, Wu MR, Pery E, Binder-Nissim A, Suzuki HI, Stupp D, Wehrspaun C, Tabach Y, Sharp PA, Lu TK. Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy. Cell. PMID 29056342 DOI: 10.1016/J.Cell.2017.09.049 |
0.557 |
|
| 2017 |
Lee G, Atia L, Lan B, Sharma Y, Nissim L, Wu MR, Pery E, Lu TK, Park CY, Butler JP, Fredberg JJ. Contact guidance and collective migration in the advancing epithelial monolayer. Connective Tissue Research. PMID 28945485 DOI: 10.1080/03008207.2017.1384471 |
0.3 |
|
| 2016 |
Sentman ML, Murad JM, Cook WJ, Wu MR, Reder J, Baumeister SH, Dranoff G, Fanger MW, Sentman CL. Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice. Journal of Immunology (Baltimore, Md. : 1950). PMID 27849169 DOI: 10.4049/Jimmunol.1600769 |
0.677 |
|
| 2015 |
Wu MR, Zhang T, Gacerez AT, Coupet TA, DeMars LR, Sentman CL. B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity. Journal of Immunology (Baltimore, Md. : 1950). 194: 5305-11. PMID 25911747 DOI: 10.4049/Jimmunol.1402517 |
0.715 |
|
| 2015 |
Wu MR, Zhang T, DeMars LR, Sentman CL. B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity. Gene Therapy. PMID 25830550 DOI: 10.1038/Gt.2015.29 |
0.729 |
|
| 2015 |
Wu MR, Zhang T, Alcon A, Sentman CL. DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma. Cancer Immunology, Immunotherapy : Cii. 64: 409-18. PMID 25549845 DOI: 10.1007/S00262-014-1648-2 |
0.728 |
|
| 2014 |
Wu MR, Cook WJ, Zhang T, Sentman CL. Targeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles. Nanotechnology. 25: 475101. PMID 25371538 DOI: 10.1088/0957-4484/25/47/475101 |
0.685 |
|
| 2013 |
Spear P, Wu MR, Sentman ML, Sentman CL. NKG2D ligands as therapeutic targets. Cancer Immunity. 13: 8. PMID 23833565 |
0.63 |
|
| 2012 |
Zhang T, Wu MR, Sentman CL. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. Journal of Immunology (Baltimore, Md. : 1950). 189: 2290-9. PMID 22851709 DOI: 10.4049/Jimmunol.1103495 |
0.689 |
|
| Show low-probability matches. |